Weekly highlight of CEO buys. Related Companies: GFI Group Inc. (GFIG, Financial), Vail Resorts Inc. (MTN, Financial), Omrix Biopharmaceuticals Inc. (OMRI, Financial), Affirmative Insurance Holdings Inc. (AFFM, Financial), Cell Therapeutics Inc. (CTIC, Financial).
GFI Group Inc. (GFIG): Chairman and CEO, Director, 10% Owner Michael Gooch Bought 20,000 Shares
Shares of the brokerage firm GFI Group, Inc. (GFIG) made a huge 37% drop to $41.35 on Monday due to a trading mishap regarding its trading policies. The company’s 2007 fourth quarter income jumped 88% to $25.2 million or $0.84 per diluted share compared to $16.0 million or $0.55 from a year ago. The annual income rose 55% to $94.9 million or $3.18 per diluted share compared to $70.6 million or $2.42 a share.
Chairman and CEO, Director, 10% Owner of GFI Group Inc. Michael Gooch bought 20,000 shares during the past week at $62.62. This month, Directors Colin Heffron, Geoffery Kalish, Marisa Cassoni, and John R. Macdonald bought 5,000 shares, 2,007 shares, 2,000 shares, and 1,700 shares respectively between $53.99 and $65.24.
GFI Group Inc. has a market cap of $1.85 billion; its shares were traded at around $62.93 with a P/E ratio of 19.68 and P/S ratio of 1.92.
Vail Resorts Inc. (MTN): CEO, Director Robert A. Katz Bought 23,600 Shares
The largest ski resort operator Vail Resorts, Inc. (MTN) reported that their second quarter earnings fall short on the early season. Income for the quarter was down 3.2% at $51.3 million or $1.31 a share compared to $53 million or $1.35 a share. The resort’s 2007 annual membership grew 53% to 61.4 million subscribers compared to the prior year.
John Keeley, Third Avenue Management, Ron Baron, and George Soros currently own MTN shares.
CEO, Director Robert A. Katz bought 23,600 shares of MTN stock on 3/20/08 at $43.27.
Vail Resorts Inc. has a market cap of $1.83 billion; its shares were traded at around $45.88 with a P/E ratio of 26.26 and P/S ratio of 1.97.
Omrix Biopharmaceuticals Inc. (OMRI): CEO, Director Robert Taub Bought 80,000 Shares
Omrix Biopharmaceuticals, Inc. (OMRI), a biopharmaceutical company, posted lower fourth quarter results, despite a 14% rise on revenue to $20.6 million. OMRI earned $3.3 million or $0.19 per share compared with $6.4 million or $0.41 per share from the same period a year ago. The company faced higher costs, which cut into profits. For the 2007 year, the company earned $11.9 million or $0.69 a share compared to $23.1 million or $1.65 a share from 2006.
CEO, Director Robert Taub bought 80,000 shares of OMRI stock on 3/20/08 at $12.24. Director Philippe Romagnoli bought 22,190 shares on 3/20/08 at $12.16 and EVP V. Marc Droppert bought 4,000 shares on 3/18/08 at $12.48. Insider sells were made by Former SVP Michael Burshtine, who sold a total of 113,637 shares on 1/04/08 at around $34, SVP Nissim Mashiach, who sold 9,091 shares on 12/11/07 at $38, and General Counsel Nanci Prado, who sold 9,000 shares on 11/08/07 at $37.51.
Omrix Biopharmaceuticals Inc. has a market cap of $233.43 million; its shares were traded at around $13.54 with a P/E ratio of 19.77 and P/S ratio of 3.74.
Affirmative Insurance Holdings Inc. (AFFM): CEO, Director Kevin R. Callahan Bought 20,000 Shares
Affirmative Insurance Holdings, Inc. (AFFM) reported a fourth quarter net income of $1.463 million and an annual 2007 net income of $9.669 million compared to $9.744 million from a year ago. In 2007, the auto insurance company completed the acquisition of the car insurance distributor USAgencies LLC for $199.1 million.
CEO, Director Kevin R. Callahan bought 20,000 shares of AFFM stock on 3/19/08 at $7.81. EVPs Robert Bondi, Michael J. Mcclure, and M. Sean Mcpadden bought 10,000 shares, 2,000 shares, and 1,400 shares, correspondingly at $7.51 to $7.93.
Affirmative Insurance Holdings Inc. has a market cap of $121.62 million; its shares were traded at around $7.88 with a P/E ratio of 12.54 and P/S ratio of 0.25. The dividend yield of Affirmative Insurance Holdings Inc. stocks is 1.1%.
Cell Therapeutics Inc. (CTIC): President and CEO, Director James A. Bianco Bought 177,900 Shares
The biotech company Cell Therapeutics, Inc. (CTIC) purchased Zevalin for $30 million from Biogen Idec Inc. to market the cancer drug. Zevalin is an FDA-approved radio-immunotherapeutic drug for treating lymphoma. CTIC made a 2007 fourth quarter loss of $39 million or $0.74 a share compared to a loss of $35.6 million or $1.00 a share from 2006. The 2007 annual loss totaled $148.3 million or $3.27 a share compared to a loss of $135.8 million or $4.84 a share in 2006.
President and CEO, Director James A. Bianco bought 177,900 shares of CTIC stock on 3/19/08 at $0.55. Also, Director Phillip M. Nudelman PhD. bought 25,000 shares of CTIC stock on 3/18/08 at $0.57.
Cell Therapeutics Inc. has a market cap of $35.94 million; its shares were traded at around $0.64 with P/S ratio of 285.07.
GFI Group Inc. (GFIG): Chairman and CEO, Director, 10% Owner Michael Gooch Bought 20,000 Shares
Shares of the brokerage firm GFI Group, Inc. (GFIG) made a huge 37% drop to $41.35 on Monday due to a trading mishap regarding its trading policies. The company’s 2007 fourth quarter income jumped 88% to $25.2 million or $0.84 per diluted share compared to $16.0 million or $0.55 from a year ago. The annual income rose 55% to $94.9 million or $3.18 per diluted share compared to $70.6 million or $2.42 a share.
Chairman and CEO, Director, 10% Owner of GFI Group Inc. Michael Gooch bought 20,000 shares during the past week at $62.62. This month, Directors Colin Heffron, Geoffery Kalish, Marisa Cassoni, and John R. Macdonald bought 5,000 shares, 2,007 shares, 2,000 shares, and 1,700 shares respectively between $53.99 and $65.24.
GFI Group Inc. has a market cap of $1.85 billion; its shares were traded at around $62.93 with a P/E ratio of 19.68 and P/S ratio of 1.92.
Vail Resorts Inc. (MTN): CEO, Director Robert A. Katz Bought 23,600 Shares
The largest ski resort operator Vail Resorts, Inc. (MTN) reported that their second quarter earnings fall short on the early season. Income for the quarter was down 3.2% at $51.3 million or $1.31 a share compared to $53 million or $1.35 a share. The resort’s 2007 annual membership grew 53% to 61.4 million subscribers compared to the prior year.
John Keeley, Third Avenue Management, Ron Baron, and George Soros currently own MTN shares.
CEO, Director Robert A. Katz bought 23,600 shares of MTN stock on 3/20/08 at $43.27.
Vail Resorts Inc. has a market cap of $1.83 billion; its shares were traded at around $45.88 with a P/E ratio of 26.26 and P/S ratio of 1.97.
Omrix Biopharmaceuticals Inc. (OMRI): CEO, Director Robert Taub Bought 80,000 Shares
Omrix Biopharmaceuticals, Inc. (OMRI), a biopharmaceutical company, posted lower fourth quarter results, despite a 14% rise on revenue to $20.6 million. OMRI earned $3.3 million or $0.19 per share compared with $6.4 million or $0.41 per share from the same period a year ago. The company faced higher costs, which cut into profits. For the 2007 year, the company earned $11.9 million or $0.69 a share compared to $23.1 million or $1.65 a share from 2006.
CEO, Director Robert Taub bought 80,000 shares of OMRI stock on 3/20/08 at $12.24. Director Philippe Romagnoli bought 22,190 shares on 3/20/08 at $12.16 and EVP V. Marc Droppert bought 4,000 shares on 3/18/08 at $12.48. Insider sells were made by Former SVP Michael Burshtine, who sold a total of 113,637 shares on 1/04/08 at around $34, SVP Nissim Mashiach, who sold 9,091 shares on 12/11/07 at $38, and General Counsel Nanci Prado, who sold 9,000 shares on 11/08/07 at $37.51.
Omrix Biopharmaceuticals Inc. has a market cap of $233.43 million; its shares were traded at around $13.54 with a P/E ratio of 19.77 and P/S ratio of 3.74.
Affirmative Insurance Holdings Inc. (AFFM): CEO, Director Kevin R. Callahan Bought 20,000 Shares
Affirmative Insurance Holdings, Inc. (AFFM) reported a fourth quarter net income of $1.463 million and an annual 2007 net income of $9.669 million compared to $9.744 million from a year ago. In 2007, the auto insurance company completed the acquisition of the car insurance distributor USAgencies LLC for $199.1 million.
CEO, Director Kevin R. Callahan bought 20,000 shares of AFFM stock on 3/19/08 at $7.81. EVPs Robert Bondi, Michael J. Mcclure, and M. Sean Mcpadden bought 10,000 shares, 2,000 shares, and 1,400 shares, correspondingly at $7.51 to $7.93.
Affirmative Insurance Holdings Inc. has a market cap of $121.62 million; its shares were traded at around $7.88 with a P/E ratio of 12.54 and P/S ratio of 0.25. The dividend yield of Affirmative Insurance Holdings Inc. stocks is 1.1%.
Cell Therapeutics Inc. (CTIC): President and CEO, Director James A. Bianco Bought 177,900 Shares
The biotech company Cell Therapeutics, Inc. (CTIC) purchased Zevalin for $30 million from Biogen Idec Inc. to market the cancer drug. Zevalin is an FDA-approved radio-immunotherapeutic drug for treating lymphoma. CTIC made a 2007 fourth quarter loss of $39 million or $0.74 a share compared to a loss of $35.6 million or $1.00 a share from 2006. The 2007 annual loss totaled $148.3 million or $3.27 a share compared to a loss of $135.8 million or $4.84 a share in 2006.
President and CEO, Director James A. Bianco bought 177,900 shares of CTIC stock on 3/19/08 at $0.55. Also, Director Phillip M. Nudelman PhD. bought 25,000 shares of CTIC stock on 3/18/08 at $0.57.
Cell Therapeutics Inc. has a market cap of $35.94 million; its shares were traded at around $0.64 with P/S ratio of 285.07.
